

Recommendations from York and Scarborough Medicines Commissioning Committee June 2015 V1.1

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Infliximab (Remsima®) IV infusion	Ulcerative colitis, Crohn's Disease, rheumatoid arthritis as per NICE guidance.	Approved	More cost effective than originator product.	1 st line choice for new initiation and existing patients in gastroenterology. New patients only within rheumatology.	Red – hospital only	Projected savings £557,080 per annum subject to agreement
Lercanidipine tablets (various generics and Zanidip®)	Hypertension	Approved	Cost effective formulary option within its class	2 nd line after amlodipine	Green	Savings may be achieved.
Mesalazine (Salofalk® MR) granules	Ulcerative colitis	Approved	Cost effective choice, granules offer a choice where unable to swallow tablets.	Salofalk is a 1 st line option alongside Pentasa® and Octasa®.	Green	May offer savings if used in preference to Pentasa® and Mezavant® XL.
Vitamin B Compound strong tablets	Alcohol detoxification	Approved	NICE guidance only recommends for re-feeding syndrome. TEWV and Leeds York mental health no longer routinely recommend this product.	Not commissioned for this indication.	Black	Savings could be achieved by stopping

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Tapentadol prolonged released tablets (Palexia SR®)	Chronic pain	Deferred	Further clarification required upon its place in therapy (review expected September 2015)	Not recommended for prescribing until formally reviewed	Grey	Nil
Vedolizumab (Entyvio®) IV infusion	Ulcerative colitis	Approved	Approved in line with NICE TA 342	Specialist prescribing	Red	£161,445 (based on 15 patients in year 1) without PAS scheme
Apixiban (Eliquis®) tablets	Treatment and secondary prevention of DVT/PE	Approved	Approved in line with NICE TA 341	As a treatment option alongside other anticoagulant therapies.	Green	Drug cost similar to other NOACs.
Ustekinumab (Stelara®) s/c injection	Psoriatic arthritis	Approved	Approved in line with NICE TA 340	Specialist prescribing	Red	Costs similar to other biologics.
Fosfomycin (as Fosfomycin trometamol) 3g granules for oral solution	Antimicrobial	Approved	Licensed product now available	No change to formulary recommendation, only to use a licensed product.	Amber – following Clinical microbiologist recommendation	£58.55

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
COPD pathway – items listed only reflect amendments required to local formulary. Refer to COPD pathway for all treatment options. Choices reflect cost effective options.						
<i>Long acting antimuscarinic antagonists (LAMA).</i>						
Umeclidinium 55mcg inhaler (Incruse Ellipta®)	COPD	Approved	Cost effective choice with Ellipta® device offering continuity of device type through the pathway	1st choice on COPD pathway	Green	
Glycopyrronium 44mcg inhaler (Seebri Breezhaler®)	COPD	Approved	Cost effective LAMA	2 nd choice in COPD pathway	Green	
Tiotropium inhaler (Spiriva Handihaler® and Spiriva Respimat®)	COPD	Approved	Not a cost effective choice within available inhaled LAMA choices.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
<i>Long acting beta agonists (LABA)</i>						
Formoterol 6mcg and 12mcg (Oxis® turbohaler)	COPD	Approved	Not as cost effective choice as other available inhaled LABA choices.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
Formoterol 12mcg inhaler (Foradil®)	COPD	Approved	Not as cost effective choice as other available inhaled LABA choices.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
Indacaterol 150mcg & 300mcg inhaler (Onbrez Breezhaler®)	COPD	Approved	Cost effective choice, device offers continuity with other Breezhaler® devices included in COPD pathway	3 rd choice LAMA on COPD pathway	Green	

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Olodaterol 2.5mcg inhaler (Striverdi Respimat®)	COPD	Not approved	Not a cost effective choice within available inhaled LAMA choices.	Not commissioned	Black	
Salmeterol 25mcg generic MDI inhaler	COPD	Approved	Not as cost effective choice as other available inhaled LABA choices.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
Salmeterol 50mcg (Serevent accuhaler®)	COPD	Approved	Not as cost effective choice as other available inhaled LABA choices.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
<i>Combination of long acting beta agonists and long acting antimuscarinic antagonists (LABA/LAMA)</i>						
Umeclidinium/Vilanterol 55mcg/22mcg inhaler (Anoro Ellipta®)	COPD	Approved	Cost effective choice with Ellipta® device offering continuity of device type through the pathway	1 st choice on COPD pathway	Green	There are cost savings compared to prescribing separate LABA/LAMA individual inhalers
Indacaterol/Glycopyrronium 85mcg/43mcg (Ultibro Breezhaler®)	COPD	Approved	Cost effective choice, device offers continuity with other Breezhaler® devices included in COPD pathway.	2 nd choice on COPD pathway	Green	There are cost savings compared to separate individual inhalers

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Aclidinium/ formoterol 340/12 inhaler (Duaklir Genuair®)	COPD	Approved	Cost effective choice.	2 nd choice on pathway	Green	There are cost savings compared to separate individual inhalers
<i>Long acting beta agonists and corticosteroid (LABA/ICS)</i>						
Fluticasone/vilanterol 92mcg/22mcg inhaler (Relvar Ellipta®)	COPD	Approved	Most cost-effective LABA/ICS combination and the Ellipta® device offers continuity of device type through the pathway	1 st line LABA/ICS choice on pathway.	Green	
Beclometasone/formoterol 100/6 inhaler (Fostair®)	COPD	Approved	Cost effective MDI when patients cannot tolerate a DPI device.	2 nd line LABA/ICS choice on pathway.	Green	
Budesonide/formoterol 400/12 (Symbicort Turbohaler®)	COPD	Approved	Cost effective treatment option	3 rd line choice on pathway.	Green	
Budesonide/formoterol 320/9 (DuoResp Spiromax®)	COPD	Approved	Cost-effective equivalent of Symbicort Turbohaler®, noting device is different and patient education is required.	3 rd line choice on pathway	Green	

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Fluticasone/ salmeterol 500/50 (Seretide Accuhaler®)	COPD	Approved	Continuation only for existing patients.	Continuation in existing patients only. Not listed on the COPD pathway.	Green	
Fluticasone/ salmeterol 250/25 (Seretide evohaler®)	COPD	Not approved	Not licensed for use in COPD, Fostair® is a licensed MDI for COPD.	Unlicensed. Not listed on the COPD pathway.	Black	

Additional items:

Vale of York COPD pathway

Stoma products – not approved by Vale of York CCG